Abstract: A toner image is formed on an intermediate transfer belt using a toner containing a crystalline polyester, and a recording material is interposed between the intermediate transfer belt and a secondary transfer roller having a first layer serving as a surface layer, a second layer formed of a solid layer provided on an inner peripheral side of the first layer, and a third layer formed of a porous elastic layer provided on an inner peripheral side of the second layer, and the toner image is transferred onto the recording material by the secondary transfer roller.

Abstract: A vehicle window glass with a metal terminal, includes a glass plate, an optically shielding layer on at least one of principal surfaces of the glass plate, a conductor on the optically shielding layer, a metal terminal electrically connected to the conductor via a lead-free solder, and a conductive wire fixed to the metal terminal; the metal terminal includes a pedestal portion electrically connected to a terminal connection portion via the lead-free solder; the conductor includes the terminal connection portion connected to the pedestal portion by means of a lead-free solder, and a coupling portion connected to the terminal connection portion with a narrow width than a width of the terminal connection portion in a longitudinal direction or a transverse direction of the terminal connection portion; the terminal connection portion and the coupling portion are connected together throughout at most 30% of an entire periphery of the terminal connection portion.

Abstract: The present invention provides a pentosan polysulfate having a uronic acid content of 0.0% by mass to 6.0% by mass, preferably a pentosan polysulfate having a structure represented by Formula I: wherein each R represents a hydrogen atom, —COCH3 or —SO3X, and at least one R represents —SO3X, wherein X represents a hydrogen atom or a monovalent or divalent metal, and n represents an integer of 1 or more and 30 or less; a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the pentosan polysulfate or of a pharmaceutically acceptable salt thereof. The present invention further provides a method for producing pentosan polysulfate, the method comprising the steps of depolymerizing a plant-derived raw material to obtain neutral xylooligosaccharide and sulfating the neutral xylooligosaccharide, in this order.

Abstract: A vehicle window glass with a metal terminal includes a glass plate, a conductor disposed on at least one of principal surfaces of the glass plate, and a metal terminal electrically connected to the conductor via solders. The metal terminal includes a connection portion; a first leg portion connected to the connection portion; a first base potion connected to the first leg portion; a second leg portion connected to the connection portion; a second base portion connected to the second leg portion; and a lead wire connection portion connected to the connection portion and including a rising portion and a bent portion connected to the rising portion, and a fixing portion connected to the bent portion and configured to be connected to a lead wire.

Abstract: The present invention provides a method for producing pentosan polysulfate, the method including a first step of obtaining an acidic xylooligosaccharide from a plant-derived raw material, and a second step of obtaining pentosan polysulfate from the acidic xylooligosaccharide. The first step includes a step of depolymerizing the plant-derived raw material. The second step includes a step of sulfating the acidic xylooligosaccharide. The method further includes a deacetylation step of adding a base to achieve a pH of 11 or higher. The deacetylation step is a step performed after the depolymerization step. The production method of the present invention can provide pentosan polysulfate having a low acetyl group content, and also produce pentosan polysulfate with a high yield inexpensively and efficiently.

Abstract: The present invention provides a reduced-cost method for producing an acidic xylooligosaccharide, the method including a depolymerization step of depolymerizing a plant-derived raw material and a deacetylation step of adding a base to a solution of the product of the depolymerization step to achieve a pH of 11 or higher. The present invention further provides an acidic xylooligosaccharide having an acetyl group content of 0 to 5.0 mass %. The acidic xylooligosaccharide of the present invention, which has an acetyl group content of 0 to 5.0 mass %, can be used as a starting material in a production method to thereby obtain pentosan polysulfate with a high yield.

Abstract: The present invention provides a novel topical moisturizing preparation containing as an active ingredient at least one selected from pentosan polysulfate; pharmaceutically acceptable salts of pentosan polysulfate; and pharmaceutically acceptable solvates thereof. The topical moisturizing preparation of the present invention, which contains a substance free of animal-derived components as an active ingredient, can be produced as a topical moisturizing preparation free of animal-derived components, as needed.

Abstract: The present invention provides pentosan polysulfate having a weight average molecular weight of 5000 or less and a content of acetyl groups of 0% to 2.0% by mass, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. The pentosan polysulfate of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof exhibits an anti-Xa activity and an anti-Xa/anti-IIa activity ratio, which are suitable for practical use, and is useful as a pharmaceutical composition such as an anticoagulant.

Abstract: The present invention provides a method for producing pentosan polysulfate, the method including a first step of obtaining an acidic xylooligosaccharide from a plant-derived raw material, and a second step of obtaining pentosan polysulfate from the acidic xylooligosaccharide. The first step includes a step of depolymerizing the plant-derived raw material. The second step includes a step of sulfating the acidic xylooligosaccharide. The method further includes a deacetylation step of adding a base to achieve a pH of 11 or higher. The deacetylation step is a step performed after the depolymerization step. The production method of the present invention can provide pentosan polysulfate having a low acetyl group content, and also produce pentosan polysulfate with a high yield inexpensively and efficiently.

Abstract: The present invention provides a pentosan polysulfate having a uronic acid content of 0.0% by mass to 6.0% by mass, preferably a pentosan polysulfate having a structure represented by Formula I: wherein each R represents a hydrogen atom, —COCH3 or —SO3X, and at least one R represents —SO3X, wherein X represents a hydrogen atom or a monovalent or divalent metal, and n represents an integer of 1 or more and 30 or less; a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable solvate of the pentosan polysulfate or of a pharmaceutically acceptable salt thereof. The present invention further provides a method for producing pentosan polysulfate, the method comprising the steps of depolymerizing a plant-derived raw material to obtain neutral xylooligosaccharide and sulfating the neutral xylooligosaccharide, in this order.

Abstract: The present invention provides a reduced-cost method for producing an acidic xylooligosaccharide, the method including a depolymerization step of depolymerizing a plant-derived raw material and a deacetylation step of adding a base to a solution of the product of the depolymerization step to achieve a pH of 11 or higher. The present invention further provides an acidic xylooligosaccharide having an acetyl group content of 0 to 5.0 mass %. The acidic xylooligosaccharide of the present invention, which has an acetyl group content of 0 to 5.0 mass %, can be used as a starting material in a production method to thereby obtain pentosan polysulfate with a high yield.

Abstract: The present invention provides a novel topical moisturizing preparation containing as an active ingredient at least one selected from pentosan polysulfate; pharmaceutically acceptable salts of pentosan polysulfate; and pharmaceutically acceptable solvates thereof. The topical moisturizing preparation of the present invention, which contains a substance free of animal-derived components as an active ingredient, can be produced as a topical moisturizing preparation free of animal-derived components, as needed.

Abstract: The present invention provides pentosan polysulfate having a weight average molecular weight of 5000 or less and a content of acetyl groups of 0% to 2.0% by mass, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. The pentosan polysulfate of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof exhibits an anti-Xa activity and an anti-Xa/anti-IIa activity ratio, which are suitable for practical use, and is useful as a pharmaceutical composition such as an anticoagulant.

Abstract: Provided is a clip that does not require a through hole to be formed in one of the two component parts that are to be connected, and is provided with a small thickness so that the spacing between the two component parts may be minimized. The clip includes a first part including a plate-shaped first base and a first engagement piece projecting from a surface of the first base, a free end part of the first engagement piece being formed with an engagement projection; and a second part including a plate-shaped second base and a second engagement piece projecting from a surface of the second base, a free end part of the second engagement piece being formed with an overhang portion configured to cooperate with the engagement projection; wherein a receiving hole is formed at least in one of the first base and the second base, and is configured to receive at least a part of the engagement piece projecting from the other of the first base and the second base.

Abstract: A baffle plate for a differential device disposed inside a differential case, includes a baffle plate main member made of synthetic resin and adapted to be disposed on one lateral side of a ring gear in the differential device; and an elastically deformable seal member attached to an outer peripheral edge portion of the baffle plate main member and adapted to contact a bottom wall portion of the differential case.

Abstract: A baffle plate for a differential device disposed inside a differential case, includes a baffle plate main member made of synthetic resin and adapted to be disposed on one lateral side of a ring gear in the differential device; and an elastically deformable seal member attached to an outer peripheral edge portion of the baffle plate main member and adapted to contact a bottom wall portion of the differential case.

Abstract: Provided is a clip (2, 52) which does not require a through hole to be formed in one of the two component parts that are to be connected, and is provided with a small thickness so that the spacing between the two component parts may be minimized.

Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl(meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxyl group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.

Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl(meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxyl group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.

Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl (meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxy group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.